PHILADELPHIA -- For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ...
Researchers uncover why children with asthma or multiple allergies face higher odds of reacting during oral food challenges, and how better screening can make testing safer. Study: Asthma and ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results